Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 75

Sort by

Sort Order Select

Journal Articles

A conceptual framework for managing iTTP

Richard J. Benjamin

Blood (2021) 137 (14): 1845–1846.

https://doi.org/10.1182/blood.2021011007

Published: 2021

Journal Articles

Redefining outcomes in immune TTP: an international working group consensus report

Adam Cuker, Spero R. Cataland, Paul Coppo, Javier de la Rubia, Kenneth D. Friedman, James N. George, Paul N. Knoebl, Johanna A. Kremer Hovinga, Bernhard Lӓmmle, Masanori Matsumoto, Katerina Pavenski, Flora Peyvandi, Kazuya Sakai, Ravi Sarode, Mari R. Thomas, Yoshiaki Tomiyama, Agnès Veyradier, John-Paul Westwood, Marie Scully

Blood (2021) 137 (14): 1855–1861.

https://doi.org/10.1182/blood.2020009150

Published: 2021

Includes: Supplemental data

Journal Articles

A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP

Blood (2021) 137 (6): 733–742.

https://doi.org/10.1182/blood.2020008021

Published: 2021

Includes: Supplemental data

Journal Articles

Safety of Caplacizumab in Patients Without Documented Severe ADAMTS13 Deficiency During the HERCULES Study

Javier De La Rubia, Flora Peyvandi, MD PhD, Marie Scully, Spero Cataland, MD, Paul Coppo, MD PhD, Johanna A. Kremer Hovinga, MD Prof, Paul Knoebl, MD, Ara Metjian, MD, Katerina Pavenski, MD, Hilde De Winter, MD, Rui de Passos Sousa, Filip Callewaert

Blood (2019) 134 (Supplement_1): 1093.

https://doi.org/10.1182/blood-2019-124004

Published: 2019

Journal Articles

Thrombotic Thrombocytopenia Purpura Case Series in Skmc 2016-2017

Mohamed Abu Haleeqa, MBBS, Hanan Al Raeesi, MBBS, Fatima Alkaabi, MBBS

Blood (2019) 134 (Supplement_1): 4799.

https://doi.org/10.1182/blood-2019-126479

Published: 2019

Journal Articles

Differential Effect of Rituximab on Relapse-Free Survival in De Novo and Relapsed Immune Thrombotic Thrombocytopenic Purpura in African-American and Caucasian Populations

Blood (2019) 134 (Supplement_1): 90.

https://doi.org/10.1182/blood-2019-129383

Published: 2019

Journal Articles

Therapeutic Plasma Exchange in Pediatrics for Immunologic Disorders; Tolerated and Safe Process for Pediatric Life-Threatening Conditions

Blood (2019) 134 (Supplement_1): 4986.

https://doi.org/10.1182/blood-2019-122106

Published: 2019

Journal Articles

Narratives of Patients with Fatal Outcomes During the Phase 2 TITAN and Phase 3 HERCULES Studies

Spero Cataland, MD, Marie Scully, Flora Peyvandi, MD PhD, Paul Knoebl, MD, Johanna A. Kremer Hovinga, MD Prof, Paul Coppo, MD PhD, Ara Metjian, MD, Javier De La Rubia, Katerina Pavenski, MD, Hilde De Winter, MD, Filip Callewaert

Blood (2019) 134 (Supplement_1): 4908.

https://doi.org/10.1182/blood-2019-123124

Published: 2019

Journal Articles

Plasma Levels of Histone-DNA Complex and Cell-Free DNA Predict Mortality in Patients with Immune Thrombotic Thrombocytopenic Purpura

Jingrui (Jean) Sui, MD, Konstantine Halkidis, MD PhD, Nicole K. Kocher, Lance A. Williams, III, MD, Radhika Gangaraju, MD, Bryan K. Guillory, MD, Marisa B. Marques, MD, Wenjing Cao, MD,PhD, X. Long Zheng, MD, PhD

Blood (2019) 134 (Supplement_1): 1070.

https://doi.org/10.1182/blood-2019-131585

Published: 2019

Journal Articles

Assessment of the Plasmic Score Utility for Classification of Pediatric Thrombotic Microangiopathies

Grace E Linder, MD, Steven Richard Sloan, MD PhD, Pavan Bendapudi, MD, Robert Makar, MD PhD

Blood (2019) 134 (Supplement_1): 1075.

https://doi.org/10.1182/blood-2019-130608

Published: 2019

Journal Articles

Routine Double Filtration Plasmapheresis Affects Hemostatic Proteins and Prolongs Clotting Tests

Shen Chu Xie, Anthony K.C. Chan, MBBS, FRCPC, Raimondo De Cristofaro, Alfonso Iorio, Stefano Lancellotti, Olivia Minelli, MD, Monica Sacco, Davide Matino, MD MSc

Blood (2019) 134 (Supplement_1): 1178.

https://doi.org/10.1182/blood-2019-127524

Published: 2019

Journal Articles

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Initial Immunosuppression Regimen

Katerina Pavenski, MD, Paul Knoebl, MD, Marie Scully, Johanna A. Kremer Hovinga, MD Prof, Paul Coppo, MD PhD, Flora Peyvandi, MD PhD, Spero Cataland, MD, Ara Metjian, MD, Javier De La Rubia, Hilde De Winter, MD, Rui de Passos Sousa, Filip Callewaert

Blood (2019) 134 (Supplement_1): 2365.

https://doi.org/10.1182/blood-2019-123126

Published: 2019

Journal Articles

Longitudinal Assessment of Plasma ADAMTS13 Biomarkers Helps Predict Recurrence of Immune Thrombotic Thrombocytopenic Purpura

Jingrui (Jean) Sui, MD, Wenjing Cao, MD,PhD, Mohammad S. Abdelgawwad, MD, Konstantine Halkidis, MD PhD, Nicole K. Kocher, Bryan K. Guillory, MD, Lance A. Williams, III, MD, Marisa B. Marques, MD, Radhika Gangaraju, MD, X. Long Zheng, MD, PhD

Blood (2019) 134 (Supplement_1): 2456.

https://doi.org/10.1182/blood-2019-126093

Published: 2019

Journal Articles

Predictors of Relapse and Efficacy of Rituximab in Autoimmune Thrombotic Thrombocytopenic Purpura (TTP): A Multi-Institutional Registry-Based Analysis

Lova Sun, MD, Johnathan P. Mack, MD, Ang Li, MD, Justine Ryu, MD, Vivek A Upadhyay, MD, Robert Makar, MD PhD, Pavan Bendapudi, MD

Blood (2018) 132 (Supplement 1): 375.

https://doi.org/10.1182/blood-2018-99-110656

Published: 2018

Journal Articles

Therapeutic Plasma Exchange Practices in Immune Thrombocytopenic Purpura Related Hospitalizations: Real World Practices for a Category III Apheresis Indication

Sarah Makhani, BA, Joseph Schwartz, MD MPH, Aaron Tobian, MD PhD, Saurav Chopra, Ljiljana V. Vasovic, MD, Robert Andrew Desimone, MD, Patricia Shi, MD, Shipra Kaicker, MD, Cassandra D Josephson, MD, James B. Bussel, MD, Ruchika Goel, MD MPH

Blood (2018) 132 (Supplement 1): 3757.

https://doi.org/10.1182/blood-2018-99-111425

Published: 2018

Journal Articles

Combined Elevated Anti-Adamts-13 Antibody Level and Low Adamts-13 Activity during Remission Highly Predicts Disease Relapse in a Prospective Cohort of Patients with Autoimmune Thrombotic Thrombocytopenic Purpura (TTP)

Francesca Schieppati, MD, Laura Russo, Marina Marchetti, Gloria Caldara, Shenaz Brevi, Maria Testa, Luca Barcella, Monica Carpenedo, Mariella D'Adda, Giuseppe Rossi, Chiara Savignano, Atto Billio, Massimiliano Bruno Franco, Vincenzo Toschi, Anna Falanga

Blood (2018) 132 (Supplement 1): 2443.

https://doi.org/10.1182/blood-2018-99-119317

Published: 2018

Journal Articles

Clinical Associations, Treatment, and Outcomes of Renal-Limited Thrombotic Microangiopathy

Elias Simon Saba, BS, Julia Claire Cambron, BS, Ronald S. Go, MD, Nelson Leung, MD, Meera Sridharan, MD

Blood (2018) 132 (Supplement 1): 4978.

https://doi.org/10.1182/blood-2018-99-117723

Published: 2018

Journal Articles

Single-Center Experience of the Utility of a Rapid ADAMTS13 Assay

Peter Barth, MD, Ari Pelcovits, MD, John L Reagan, MD

Blood (2017) 130 (Supplement 1): 3630.

https://doi.org/10.1182/blood.V130.Suppl_1.3630.3630

Published: 2017

Journal Articles

Projected Cost Savings of a Plasmic Score-Based Approach to Patients with Suspected Thrombotic Thrombocytopenic Purpura

Vivek A Upadhyay, MD, Benjamin Geisler, MD, Lova Sun, MD, Christopher P. Stowell, MD PhD, Lynne Uhl, MD, Richard Kaufman, MD, Robert Makar, MD PhD, Pavan Bendapudi, MD

Blood (2017) 130 (Supplement 1): 3742.

https://doi.org/10.1182/blood.V130.Suppl_1.3742.3742

Published: 2017

Journal Articles

The Impact of Detectable ADAMTS13 Inhibitor on the Clinical Presentation and Outcome of Patients with Immune Thrombotic Thrombocytopenic Purpura (iTTP): Analysis Using the United States Thrombotic Microangiopathy (USTMA) Clinical Registry

Meera Sridharan, MD, Ana G Antun, MD, Lisa Baumann Kreuziger, Assistant Professor. MD MS, Spero R Cataland, MD, Shruti Chaturvedi, MBBS,MS, Todd Clover, MD, Elizabeth Davis, Andrew Johnson, MD, Keith McCrae, MD, Ming Yeong Lim, MBBChir, J. Evan Sadler, MD PhD, Marshall A. Mazepa, MD, Ronald S Go, MD

Blood (2017) 130 (Supplement 1): 3620.

https://doi.org/10.1182/blood.V130.Suppl_1.3620.3620

Published: 2017

NARROW

A conceptual framework for managing iTTP

Redefining outcomes in immune TTP: an international working group consensus report

A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP

Safety of Caplacizumab in Patients Without Documented Severe ADAMTS13 Deficiency During the HERCULES Study

Thrombotic Thrombocytopenia Purpura Case Series in Skmc 2016-2017

Differential Effect of Rituximab on Relapse-Free Survival in De Novo and Relapsed Immune Thrombotic Thrombocytopenic Purpura in African-American and Caucasian Populations

Therapeutic Plasma Exchange in Pediatrics for Immunologic Disorders; Tolerated and Safe Process for Pediatric Life-Threatening Conditions

Narratives of Patients with Fatal Outcomes During the Phase 2 TITAN and Phase 3 HERCULES Studies

Plasma Levels of Histone-DNA Complex and Cell-Free DNA Predict Mortality in Patients with Immune Thrombotic Thrombocytopenic Purpura

Assessment of the Plasmic Score Utility for Classification of Pediatric Thrombotic Microangiopathies

Routine Double Filtration Plasmapheresis Affects Hemostatic Proteins and Prolongs Clotting Tests

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Initial Immunosuppression Regimen

Longitudinal Assessment of Plasma ADAMTS13 Biomarkers Helps Predict Recurrence of Immune Thrombotic Thrombocytopenic Purpura

Predictors of Relapse and Efficacy of Rituximab in Autoimmune Thrombotic Thrombocytopenic Purpura (TTP): A Multi-Institutional Registry-Based Analysis

Therapeutic Plasma Exchange Practices in Immune Thrombocytopenic Purpura Related Hospitalizations: Real World Practices for a Category III Apheresis Indication

Combined Elevated Anti-Adamts-13 Antibody Level and Low Adamts-13 Activity during Remission Highly Predicts Disease Relapse in a Prospective Cohort of Patients with Autoimmune Thrombotic Thrombocytopenic Purpura (TTP)

Clinical Associations, Treatment, and Outcomes of Renal-Limited Thrombotic Microangiopathy

Single-Center Experience of the Utility of a Rapid ADAMTS13 Assay

Projected Cost Savings of a Plasmic Score-Based Approach to Patients with Suspected Thrombotic Thrombocytopenic Purpura

The Impact of Detectable ADAMTS13 Inhibitor on the Clinical Presentation and Outcome of Patients with Immune Thrombotic Thrombocytopenic Purpura (iTTP): Analysis Using the United States Thrombotic Microangiopathy (USTMA) Clinical Registry

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only